Stockholders' Equity - Additional Information (Details)

v3.25.1

Stockholders' Equity - Additional Information (Details) - USD ($)															1 Months Ended		2 Months Ended	12 Months Ended
	Dec. 13, 2024	Nov. 01, 2024	Apr. 25, 2024	Apr. 22, 2024	Mar. 28, 2024	Mar. 14, 2024	Nov. 17, 2023	Nov. 15, 2023	Nov. 13, 2023	Nov. 09, 2023	May 25, 2023	Apr. 27, 2023	Aug. 03, 2022	Aug. 01, 2022	May 31, 2022	Jan. 31, 2022	Nov. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 23, 2024	May 31, 2024	May 15, 2024	Mar. 25, 2024	Feb. 14, 2024	Sep. 01, 2023
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares authorized																		70,000,000	70,000,000
Preferred stock, shares authorized																		30,000,000	30,000,000
Common stock, par value																		$ 0.0001	$ 0.0001
Preferred stock, shares issued																		0	0
Preferred stock, par value																		$ 0.0001	$ 0.0001
Common stock, shares issued																		26,157,788	16,986,254
Warrant liability																		$ 2,690,605	$ 2,152,188
Stock compensation expense																		$ 1,912,744	$ 3,089,303
Warrants exercised, shares															394,501
Cashless exercise at fair market value per share															$ 9
Issuance of common shares upon cashless exercise of warrants, shares															315,601
Stock options outstanding																		9,769,992	7,750,152
Fair value assumptions, contractual term																		7 years
Exercise price percentage																		110.00%
Percentage of shares granted																		10.00%
Warrants exercise price, per share														$ 6.25
Warrants and rights exercisable period										May 22, 2024				Jan. 23, 2023
Class of warrant or right date from which warrants or rights expire														Jul. 27, 2027
Warrants																		$ 2,690,605	$ 2,152,188
Loss (gain) on remeasurement of warrant liability																		$ 6,682,758	$ (205,130)
Warrants issued																		4,225,099	2,853,293
Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate													2.82%
Volatility rate													77.50%
Fair value assumptions, contractual term													5 years
Warrants													$ 343,735
Maximum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term																		10 years
Warrants to purchase aggregate of common stock														100,000
2018 Stock Option Plan
Subsidiary or Equity Method Investee [Line Items]
Stock options outstanding																		1,773,912
Amended and Restated 2020 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance																		0
Stock options outstanding																		3,503,589
2021 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance														1,909,518				1,790,744	2,838,668	1,956,993
Percentage of increase in stock outstanding fully diluted											10.00%
Stock options outstanding																		4,492,491
Alumni Capital LP
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate										3.93%
Volatility rate										90.00%
Fair value assumptions, contractual term										3 years 10 months 13 days
Warrants exercise price, per share										$ 2.09
Warrant shares vested									131,578
Warrants and rights exercisable period										Nov. 10, 2023
Class of warrant or right date from which warrants or rights expire										Nov. 10, 2027
Warrants										$ 84,251
Alumni Capital LP | Laidlaw & Company Ltd
Subsidiary or Equity Method Investee [Line Items]
Issuance of common shares upon cashless exercise of warrants, shares									54,976
Warrant fee paid in cash										13,750
Warrants										$ 375,705
Loss (gain) on remeasurement of warrant liability																		$ 291,454	$ 0
Alumni Capital LP | Maximum
Subsidiary or Equity Method Investee [Line Items]
Warrants to purchase aggregate of common stock										239,234
IPO
Subsidiary or Equity Method Investee [Line Items]
Number of warrants exercised														20,520
Warrants exercise price, per share														$ 5
IPO | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Warrants																		71,672	40,211
Loss (gain) on remeasurement of warrant liability																		$ 31,461	205,130
Follow-on Offering
Subsidiary or Equity Method Investee [Line Items]
warrants exercisable																		11,243
Number of common stock Issued and sold																		22,869
Risk free interest rate														4.09%
Volatility rate														86.30%
Issuance of common shares upon cashless exercise of warrants, shares																		116,532
Fair value assumptions, contractual term														5 years
Warrants exercise price, per share														$ 2.81
Warrants and rights exercisable period														Oct. 24, 2023
Class of warrant or right date from which warrants or rights expire														Apr. 24, 2028
Class of warrant or right additional purchase aggregate of common stock														241,109
Follow-on Offering | Maximum
Subsidiary or Equity Method Investee [Line Items]
Warrants to purchase aggregate of common stock														127,775
Follow-on Offering | ThinkEquity LLC
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold												2,555,500
Common stock per share												$ 2.25
Net proceeds from common stock												$ 4,156,859
At-the-Market Equity Offering
Subsidiary or Equity Method Investee [Line Items]
Common stock, par value																										$ 0.0001
Number of common stock Issued and sold																	758,388
Net proceeds from common stock																	$ 1,238,688
Warrant liability																	$ 84,251
At The Market Offering Agreement | H.C. Wainwright and Co., LLC
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold																		3,940,683
Common stock per share																		$ 2.95
Net proceeds from common stock																		$ 11,284,093
Gross proceeds from sale of common stock																		11,633,086
Commissions paid																		348,993
Private Placement
Subsidiary or Equity Method Investee [Line Items]
Common stock per share	$ 1.872	$ 2.259		$ 2.034	$ 2.295	$ 1.17
Aggregate purchase price	$ 950,000	$ 2,440,000		$ 1,000,000	$ 1,330,000	$ 2,920,000
Warrants exercise price, per share						$ 1.3
Warrants and rights exercisable period						Sep. 14, 2024
Class of warrant or right date from which warrants or rights expire						Sep. 14, 2029
Warrants																						$ 5,089,063
Loss (gain) on remeasurement of warrant liability																		3,039,463	0
Private Placement | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate						4.20%
Volatility rate						95.00%
Fair value assumptions, contractual term						5 years 6 months
Warrants						$ 2,049,600
Private Placement | Amendment Of Warrant Agreements
Subsidiary or Equity Method Investee [Line Items]
Warrants																						$ 437,031
Private Placement Offering 1
Subsidiary or Equity Method Investee [Line Items]
Gross proceeds from sale of common stock																		2,920,696
Private Placement Offering 1 | Amendment Of Warrant Agreements
Subsidiary or Equity Method Investee [Line Items]
Warrants																		199,417	0
Loss (gain) on remeasurement of warrant liability																		$ 91,840	0
Remaining warrant liability																		141,612
Private Placement Offering
Subsidiary or Equity Method Investee [Line Items]
Warrants to purchase aggregate of common stock																						437,031
Warrants and rights exercisable period	Jun. 13, 2025	May 01, 2025	Oct. 25, 2024		Sep. 28, 2024
Class of warrant or right date from which warrants or rights expire	Jun. 13, 2030	May 01, 2030	Oct. 25, 2029		Sep. 28, 2029
Private Placement Offering | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate					4.20%
Volatility rate					95.00%
Fair value assumptions, contractual term					5 years 6 months
Warrants					$ 1,190,111
Private Placement Offering | Amendment Of Warrant Agreements
Subsidiary or Equity Method Investee [Line Items]
Warrants																		$ 1,011,562				$ 1,011,562
Loss (gain) on remeasurement of warrant liability																		112,708	0
Private Placement Offering April 2024
Subsidiary or Equity Method Investee [Line Items]
Warrants																						$ 769,671
Loss (gain) on remeasurement of warrant liability																		91,572	0
Registered Direct Offering
Subsidiary or Equity Method Investee [Line Items]
Common stock, par value							$ 0.0001
Net proceeds from common stock							$ 3,400,000
Warrant liability							$ 2,000,000
Risk free interest rate							3.85%	3.84%
Volatility rate							90.00%	90.00%
Fair value assumptions, contractual term							5 years 4 months 17 days	4 years 10 months 17 days
Warrants to purchase aggregate of common stock								169,697
Warrants exercise price, per share							$ 1.86	$ 2.06
Warrants and rights exercisable period								Nov. 15, 2023
Class of warrant or right date from which warrants or rights expire								Nov. 15, 2028
Warrants							$ 1,903,915	$ 123,811										230,038	123,811
Loss (gain) on remeasurement of warrant liability																		$ 106,227	0
Registered Direct Offering | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold																		458,726
Issuance of common shares upon cashless exercise of warrants, shares							909,091
Warrants							$ 2,815,970
Loss (gain) on remeasurement of warrant liability																		$ 3,101,533	$ 0
Registered Direct Offering | Maximum
Subsidiary or Equity Method Investee [Line Items]
Warrants to purchase aggregate of common stock							2,424,243
Overallotment Option | Maximum
Subsidiary or Equity Method Investee [Line Items]
Class of warrant or right additional purchase aggregate of common stock													15,000
Common Stock
Subsidiary or Equity Method Investee [Line Items]
Issuance of restricted stock, Shares																		75,550	291,469
Issuance of common shares upon exercise of warrants, Shares															153,000	61,111
Proceeds from issuance of common stock upon exercise of warrants															$ 275,400	$ 110,000
Common Stock | Follow-on Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold																			2,555,500
Common Stock | At-the-Market Equity Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold																		3,274,360	758,388
Common Stock | At-the-Market Equity Offering | Maximum
Subsidiary or Equity Method Investee [Line Items]
Aggregate offering price																										$ 7,000,000
Common Stock | At The Market Offering Agreement | Maximum | H.C. Wainwright and Co., LLC
Subsidiary or Equity Method Investee [Line Items]
Aggregate offering price																					$ 30,000,000		$ 11,280,000	$ 4,950,000	$ 1,445,000
Common Stock | Private Placement
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	507,364	1,079,784	494,096		578,643	2,496,318
Common Stock | Private Placement Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold																		5,156,205
Common Stock | Registered Direct Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold							2,424,243
Investor Warrants | Private Placement
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	507,364	1,079,784	494,096		578,643	2,496,318
Common stock per share	$ 2.08	$ 2.51	$ 2.26		$ 2.55	$ 1.3
Investor Warrants | Private Placement Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	507,364	1,079,784	494,096		578,643
Common stock per share	$ 2.08	$ 2.51	$ 2.26																						$ 2.55
Oustside Investors Warrants | Private Placement Offering | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate			4.70%
Volatility rate			95.00%
Fair value assumptions, contractual term			5 years 6 months
Warrants			$ 677,919
Director | Private Placement | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate						4.20%
Volatility rate						95.00%
Fair value assumptions, contractual term						5 years 6 months
Warrants						$ 230,685
Director | Private Placement Offering | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate	4.25%	4.22%	4.70%
Volatility rate	95.00%	95.00%	95.00%
Fair value assumptions, contractual term	5 years 6 months	5 years 6 months	5 years 6 months
Warrants	$ 116,151	$ 494,851	$ 346,606
Director | Common Stock | 2021 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	78,418	232,800	167,157
Director | Common Stock | Private Placement Offering | 2021 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold						452,731
Non-Affiliated Investors | Private Placement Offering | Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate	4.25%	4.22%
Volatility rate	95.00%	95.00%
Fair value assumptions, contractual term	5 years 6 months	5 years 6 months
Warrants	$ 635,345	$ 1,800,389
Non-Affiliated Investors | Common Stock | Private Placement Offering
Subsidiary or Equity Method Investee [Line Items]
Number of common stock Issued and sold	428,946	846,984	326,939			2,043,587
Restricted Stock Awards
Subsidiary or Equity Method Investee [Line Items]
Stock compensation expense																		$ 179,490	$ 731,661
Shares granted																		75,550	291,469
Unvested shares																		0	0
MAIA Stock Warrants
Subsidiary or Equity Method Investee [Line Items]
Warrant modification, value																$ 144,497
Deemed dividend on warrant modification																				$ 450,578
Employee Stock Option
Subsidiary or Equity Method Investee [Line Items]
Weighted-average fair value																		$ 2.41	$ 2.55
Unrecognized compensation																		$ 2,667,623
Unrecognized compensation expense, recognized period																		2 years 2 months 12 days
Employee Stock Option | Maximum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term																		6 years 3 months	6 years 3 months
Employee Stock Option | Minimum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term																		5 years	5 years